Provenge Immunotherapy Increases Overall Survival in African-American Men with Metastatic Prostate Cancer

Provenge Immunotherapy Increases Overall Survival in African-American Men with Metastatic Prostate Cancer
African-American men with metastatic castrate-resistant prostate cancer survive significantly longer than Caucasian men when treated with Provenge, according to new findings from Dendreon’s PROCEED registry, which is following patients' outcomes in a real-world treatment setting. The new results were recently presented at the 112th American Urological Association (AUA) Annual Meeting held May 12-16 in Boston. Provenge is the only immunotherapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. The drug works by reprogramming the body’s immune cells to attack advanced prostate cancer cells. The new results show that African-American patients had extended overall survival when treated with Provenge compared to Caucasian patients (37.3 months vs. 28.0 months). This represents a difference of 9.3 months. Additionally, looking only at patients with low PSA levels at the time of Provenge treatment, African-American men again showed an extended overall survival of 20.9 months compared to Caucasian men – 54.3 months vs. 33.4 months, respectively. “These new findings are very encouraging given that African-American men with prostate cancer have a mortality rate more than twice as high as Caucasian men and historically have presented with aggressive disease and have had worse outcomes in both real-world settings and controlled clinical trials,” A. Oliver Sartor, MD, the study's lead author, said in a press release. "The fact that we saw an even greate
Subscribe or to access all post and page content.

3 comments

  1. Herschell Atkinson says:

    Is there any website I can go to to get updated results of men that took the Provenge protocol and then followed up with Xtandi.
    I did provenge in November 2015 and then started Xtandi in January 2016.

Leave a Comment

Your email address will not be published. Required fields are marked *